Skip to main content
Premium Trial:

Request an Annual Quote

AlgoNomics Gives Genmab Access to Bioinformatics Platform in Agreement

This article corrects the fact that AlgoNomics' platform -- not Genmab's platform, as originally reported -- is intended for T-cell epitope identification.

NEW YORK, May 12 (GenomeWeb News) - AlgoNomics  has granted Genmab access to its Epibase structural bioinformatics platform for three years, the companies said today.


The AlgoNomics platform is intended for T-cell epitope identification. Epibase can be used "to validate the intrinsically low immunogenicity of our fully human therapeutic antibody leads that are currently in clinical and pre-clinical phases," said Jan van de Winkel, Genmab CSO, in a statement.


Financial details of the agreement were not disclosed.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.